Strategies for optimizing combinations of molecularly targeted anticancer agents

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Hundreds of new cancer-specific molecularly targeted agents are emerging.
• Evaluating these agents individually and in various combinations presents significant development challenges.

Purpose of the Study:

• To outline a development strategy for targeted-agent combinations.
• To identify challenges in the preclinical and clinical evaluation of targeted-agent combinations.
• To discuss potential approaches to overcome these challenges.

Main Methods:

• This study considers the crucial elements of a development strategy for targeted-agent combinations.
• It describes issues that pose challenges to rational preclinical and clinical evaluation.
• It discusses possible approaches to overcoming these challenges.

Main Results:

• The sheer number of potential drug combinations necessitates a strategic approach.
• Rational evaluation requires addressing specific preclinical and clinical challenges.
• Prioritization of combinations is essential for efficient drug development.

Conclusions:

• A robust strategy is vital for navigating the complexities of targeted-agent combination development.
• Overcoming evaluation challenges will accelerate the delivery of novel cancer therapies.
• Prioritizing promising combinations ensures efficient resource allocation in drug development.